Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
about
Imatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaCovariate pharmacokinetic model building in oncology and its potential clinical relevance.Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Monitoring imatinib plasma concentrations in chronic myeloid leukemiaCYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursEffects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Current status of therapy for chronic myeloid leukemia: a review of drug development.Clinical development of imatinib: an anticancer drug.Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group.Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.Pharmacology and pharmacokinetics of imatinib in pediatric patients.An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
P2860
Q24186877-C9F0CFCE-E0CD-4434-8DC3-D9BEF8BB04D2Q24241730-65AF64C3-8432-4B74-A771-A3C37FBB8CC7Q27687599-6451026F-83B6-4CE3-9E1E-7DAA962986FAQ33557847-D915B04D-0BF7-4B63-8050-9AB2F2A9A402Q34339623-C7B119CA-A7BB-4CB9-B5D7-C642353B0365Q35607790-98C98FA1-DC11-44B5-ADEC-BCA2D01ADE42Q35827616-2284D0E7-A649-4705-95CA-0D029ACF6B09Q35827640-1A76604B-BFFC-498E-8C2D-EC3DE226BAA2Q35846126-471B45EF-ED50-409C-A33C-65EE21851390Q35930616-C4731C0A-0156-465B-9264-F6ECEE0159A5Q36153597-EC179EC3-6D5A-490E-96BE-E1F9E54FD682Q36229161-9137E126-E65B-4FA0-9CDF-3F74EFA5C01CQ36243653-4D88884C-5A68-4AFA-AC51-F4A6B23B6FE2Q36407123-F84C0FCA-BD3F-4688-A8C8-A8A059CF9BACQ36667469-B1D12DDB-033D-4064-873C-3FC61D73B47EQ36729934-9E3DB51B-7630-446E-855A-C65A991727C3Q36792630-BD32FB3F-5B31-4ABC-B5FF-B28A1D1189D9Q36822880-2216FF15-68A4-4E6C-9C7A-1A26AE379842Q37163550-F5DD43E5-34DE-4B7B-8084-2DC13BE53339Q37179388-37F2F14D-F95F-4C5E-B185-BA2E7CD7F9E0Q37474460-B54B6320-0254-4F21-BFF7-89750E87C036Q37504935-03290F33-1F9A-43BC-BC7F-9144DFC7135EQ37862942-A1DD7A03-8423-4690-8EFD-E377F7067258Q37896606-386A7950-7736-4313-9876-58F06327BCC1Q38720418-2B11D4B4-45A3-4EFA-8C79-D1831F5C9CC9Q38724254-642B117A-CD56-44E9-BB69-0B15A569D601Q39125275-830CB739-1B28-4779-9FF3-59D71A4026B4Q39651800-143E04E5-DCE5-4E7D-818F-3CB9B5DDD528Q40213114-F8712122-D73C-4F9F-A0C8-B594528F8038Q40721053-30980CA6-B027-4B2B-BCFB-375F3380343AQ41404164-A3A807EC-6B5C-4D6B-8161-FCE489D99439Q42283688-55165D13-DF20-46E3-83D3-09A4A4621AADQ43288117-32901234-6B75-4DE2-B93E-88D904A3A868Q43841175-25557996-2090-41E2-B711-6E4E614FA01DQ46047555-B1538878-5E3E-409E-8035-EEB734580F13Q46380705-072906E8-9025-4288-91C6-DD1351D14022Q50094239-1FC8B0B8-EB05-489C-85D2-DA97E137225BQ50593562-49C8C93B-3948-4792-9B84-A7D7FC0739BAQ50600192-0A534258-E6B6-473F-96C5-6A4255B7FABBQ51088241-DC51693D-A021-45F2-86E5-1C7413377454
P2860
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Population pharmacokinetics of ...... results of a phase III study.
@ast
Population pharmacokinetics of ...... results of a phase III study.
@en
type
label
Population pharmacokinetics of ...... results of a phase III study.
@ast
Population pharmacokinetics of ...... results of a phase III study.
@en
prefLabel
Population pharmacokinetics of ...... results of a phase III study.
@ast
Population pharmacokinetics of ...... results of a phase III study.
@en
P2093
P2860
P1476
Population pharmacokinetics of ...... results of a phase III study.
@en
P2093
A E Bolton
A Racine-Poon
G-J Riviere
H Schmidli
I Gathmann
IRIS Study Group
R Capdeville
P2860
P356
10.1111/J.1365-2125.2005.02372.X
P407
P577
2005-07-01T00:00:00Z